Opendata, web and dolomites

Simecos SIGNED

A New Adjuvant Nutraceutical from the North Atlantic Ocean for Breast, Lung and Pancreatic Cancer Patients

Total Cost €


EC-Contrib. €






 Simecos project word cloud

Explore the words cloud of the Simecos project. It provides you a very rough idea of what is the project "Simecos" about.

iceland       compounds    ykl    siglufj    discovered    fishery    worsen    village    2020    82    pancreatic    anti    supplements    2024    confirmed    north    patients    opportunity    rdur    industry    survival    lung       profit    clinical    marine    effect    exoskeleton    nutraceutical    18m    crisis    diagnosed    roi    chos    breast    solutions    respectively    proven    chitinase    30    fatigue    cancer    diseases    market    quality    95    780    investment    levels    inflammatory    complementary    human    optimise    inflammation    pain    validated    shrimp    prove    genis    considering    manufacturing    return    clinically    chitin    purified    trial    inhibition    forefront    chitooligosaccharides    molecules    started    vivo    business    budget    hence    biotechnology    2008    tumour    treatment    entail    ouml    20    pay    adjuvant    biological    validate    atlantic    enzyme    ph1    effectiveness    expansion    2002    simecos    vitro    decrease    trade    life    health    fishing    therapeutic    45m    give    extracted    chemotherapy    rates    thanks    feasibility    ph2   

Project "Simecos" data sheet

The following table provides information about the project.


Organization address
address: ADALGOTU 34
postcode: 580
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Project website
 Total cost 2˙180˙387 €
 EC max contribution 1˙526˙271 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2020-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENIS HF IS (SIGLUFJORDUR) coordinator 1˙526˙271.00


 Project objective

Genis is based in Siglufjördur, a village in the North Iceland traditionally focused on the fishing industry. After the fishery crisis worsen in 2008, Siglufjördur started to pay attention to the marine biotechnology, with Genis at the forefront. Hence, since 2002, we develop health products based in T-ChOS™ (Therapeutic Chitooligosaccharides), which are compounds obtained from chitin extracted from the North Atlantic shrimp exoskeleton. T-ChOS™ show a strong anti-inflammatory effect based in a novel biological pathway discovered by Genis: Inhibition of the YKL-40 chitinase enzyme, whose levels are very high in several diseases as cancer. Our in vitro, in vivo and human studies prove that T-ChOS™ can decrease inflammation and enhance tumour response to chemotherapy. During the Ph1 project, we confirmed the feasibility of developing a nutraceutical based on T-ChOS™ to use as an adjuvant to chemotherapy in cancer patients. In this Ph2 project, we aim to optimise manufacturing, validate through a clinical trial and bring to market SIMECOS: A nutraceutical for cancer patients derived from chitin purified T-ChOS™ molecules. SIMECOS targets lung, breast and pancreatic cancer patients, with survival rates after 5-year of 20%, 82.2% and 5.2%, respectively. SIMECOS is expected to increase their quality of life, thanks to its proven effects to decrease pain and fatigue. The high trends (30%-95%) among cancer patients to use complementary supplements entail a great business opportunity for SIMECOS as in Europe, there are more than 780,000 patients per year diagnosed with breast, pancreatic and lung cancer looking for solutions to decrease chemotherapy side effects and improve the effectiveness of their treatment. Clinically validated SIMECOS will help these patients. We expect SIMECOS to reach the market in 2020. By 2024, after our European expansion, SIMECOS will give a profit of €10.45M and considering a Phase 2 budget of €2.18M, the return-on-investment (ROI) will be 9.9


List of deliverables.
SIMECOS web page Websites, patent fillings, videos etc. 2020-03-19 15:44:56

Take a look to the deliverables list in detail:  detailed list of Simecos deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIMECOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIMECOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More